MX349005B - Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. - Google Patents
Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.Info
- Publication number
- MX349005B MX349005B MX2014002204A MX2014002204A MX349005B MX 349005 B MX349005 B MX 349005B MX 2014002204 A MX2014002204 A MX 2014002204A MX 2014002204 A MX2014002204 A MX 2014002204A MX 349005 B MX349005 B MX 349005B
- Authority
- MX
- Mexico
- Prior art keywords
- reducing
- immunoglobulin composition
- plasma
- derived immunoglobulin
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un método para reducir el contenido del Factor XI (FXI) y/o del Factor XIa (FXIa) en una composición de inmunoglobulinas derivada de plasma, caracterizado porque comprende los pasos de: (a) poner en contacto una composición inmunoglobulinas derivada de plasma que comprende inmunoglobulinas IgG y RXI y/o FXIa con una resina de intercambio catiónico dispuesta en una columna de cromatografía bajo una primera condición de solución que comprende un pH no mayor que 6.0 y una conductividad no mayor que 11 mS/cm para unir las inmunoglobulinas IgG y por lo menos una fracción de FXI y/o FXIa a la resina de intercambio catiónico, (b) eluir las inmunoglobulinas de la resina de intercambio catiónico poniendo en contacto la resina de intercambio catiónico con una solución amortiguadora de elución que comprende un pH de por lo menos 7.5 y una conductividad de por lo menos 15 mS/cm para formar una eluato que comprende una porción de cabeza o delantera y una porción de estabilización o rezagada; y (c) recolectar la porción de cabeza del eluato separadamente de la porción de estabilización del eluato, en donde la porción de cabeza del eluato comprende una composición de inmunoglobulina IgG que tiene una cantidad reducida de actividad amidolítica en comparación con la composición de partida y la porción de estabilidad amidolítica en comparación con la porción de cabeza del eluato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527974P | 2011-08-26 | 2011-08-26 | |
| PCT/US2012/052567 WO2013033042A1 (en) | 2011-08-26 | 2012-08-27 | Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002204A MX2014002204A (es) | 2014-06-11 |
| MX349005B true MX349005B (es) | 2017-07-06 |
Family
ID=46970397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002204A MX349005B (es) | 2011-08-26 | 2012-08-27 | Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9403899B2 (es) |
| EP (1) | EP2748193B1 (es) |
| JP (1) | JP6165143B2 (es) |
| KR (1) | KR101949553B1 (es) |
| CN (1) | CN103874708B (es) |
| AR (1) | AR087953A1 (es) |
| AU (1) | AU2012300220C1 (es) |
| BR (1) | BR112014004445B1 (es) |
| CA (1) | CA2846599A1 (es) |
| CL (1) | CL2014000480A1 (es) |
| CO (1) | CO6920256A2 (es) |
| EA (1) | EA030251B1 (es) |
| ES (1) | ES2624485T3 (es) |
| HK (1) | HK1199267A1 (es) |
| IL (1) | IL231083B (es) |
| MX (1) | MX349005B (es) |
| MY (1) | MY165164A (es) |
| SG (1) | SG11201400233TA (es) |
| TW (1) | TWI610937B (es) |
| WO (1) | WO2013033042A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| EP3118210B1 (en) * | 2014-03-11 | 2019-11-13 | Green Cross Holdings Corporation | Method for purifying immunoglobulin |
| ES2785375T3 (es) | 2014-03-11 | 2020-10-06 | Green Cross Holdings Corp | Procedimiento de purificación de inmunoglobulina |
| EP3275897A1 (en) * | 2016-07-27 | 2018-01-31 | Biotest AG | Process for preparing immunoglobulin compositions |
| KR101941974B1 (ko) * | 2016-11-18 | 2019-01-24 | 주식회사 녹십자 | 혈장 단백질 정제시 fxi의 제거방법 |
| US11814442B2 (en) | 2017-06-12 | 2023-11-14 | Kamada Ltd. | Immunoglobulin compositions and process for obtaining the same |
| TW202400621A (zh) * | 2022-05-02 | 2024-01-01 | 日商武田藥品工業股份有限公司 | 經由超濾自血漿製備科恩池濃縮物之方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (es) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| JPS5598117A (en) * | 1979-01-17 | 1980-07-25 | Chemo Sero Therapeut Res Inst | Purification of gamma-globulin derivative |
| US4639513A (en) | 1984-02-02 | 1987-01-27 | Cuno Inc. | Intravenously injectable immunoglobulin G (IGG) and method for producing same |
| DK166763B1 (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| US4482483A (en) | 1983-04-06 | 1984-11-13 | Armour Pharmceutical Company | Composition of intravenous immune globulin |
| EP0168506B2 (en) | 1984-07-07 | 1998-01-07 | Armour Pharma GmbH | Process for preparing gamma globulin suitable for intravenous administration |
| DE3640513A1 (de) | 1986-11-27 | 1988-06-09 | Biotest Pharma Gmbh | Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates |
| DE3641115A1 (de) | 1986-12-02 | 1988-06-16 | Lentia Gmbh | Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| DE59309332D1 (de) | 1993-12-27 | 1999-03-04 | Rotkreuzstiftung Zentratrallab | Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| US6162904A (en) | 1997-12-24 | 2000-12-19 | Alpha Therapeutic Corporation | Manufacturing method for intraveneously administrable immune globulin and resultant product |
| TR200100303T2 (tr) * | 1998-06-09 | 2001-06-21 | Statens Serum Institut | Damardan uygulanacak immünoglobülinler üretmek için yöntem ve başka immünoglobülin ürünleri. |
| US6281336B1 (en) * | 1998-06-09 | 2001-08-28 | Statens Serum Institut | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| SE0001128D0 (sv) * | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
| CN102459331B (zh) * | 2009-05-27 | 2015-01-28 | 巴克斯特国际公司 | 生产用于皮下使用的高度浓缩的免疫球蛋白制品的方法 |
| IL212911A0 (en) * | 2011-05-16 | 2011-07-31 | Omrix Biopharmaceuticals Ltd | Immunoglobulin reduced in thrombogenic contaminants and preparation thereof |
-
2012
- 2012-08-27 CA CA2846599A patent/CA2846599A1/en not_active Abandoned
- 2012-08-27 AR ARP120103162A patent/AR087953A1/es active IP Right Grant
- 2012-08-27 WO PCT/US2012/052567 patent/WO2013033042A1/en active Application Filing
- 2012-08-27 MX MX2014002204A patent/MX349005B/es active IP Right Grant
- 2012-08-27 CN CN201280050156.XA patent/CN103874708B/zh active Active
- 2012-08-27 BR BR112014004445-7A patent/BR112014004445B1/pt active IP Right Grant
- 2012-08-27 ES ES12768938.8T patent/ES2624485T3/es active Active
- 2012-08-27 EA EA201400273A patent/EA030251B1/ru not_active IP Right Cessation
- 2012-08-27 US US13/595,967 patent/US9403899B2/en active Active
- 2012-08-27 TW TW101130949A patent/TWI610937B/zh active
- 2012-08-27 MY MYPI2014000533A patent/MY165164A/en unknown
- 2012-08-27 JP JP2014527355A patent/JP6165143B2/ja active Active
- 2012-08-27 EP EP12768938.8A patent/EP2748193B1/en active Active
- 2012-08-27 SG SG11201400233TA patent/SG11201400233TA/en unknown
- 2012-08-27 AU AU2012300220A patent/AU2012300220C1/en active Active
- 2012-08-27 KR KR1020147007936A patent/KR101949553B1/ko active IP Right Grant
-
2014
- 2014-02-23 IL IL231083A patent/IL231083B/en active IP Right Grant
- 2014-02-26 CL CL2014000480A patent/CL2014000480A1/es unknown
- 2014-03-20 CO CO14060700A patent/CO6920256A2/es unknown
- 2014-12-22 HK HK14112763.4A patent/HK1199267A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140062088A (ko) | 2014-05-22 |
| JP2014525417A (ja) | 2014-09-29 |
| TWI610937B (zh) | 2018-01-11 |
| EA201400273A1 (ru) | 2014-08-29 |
| MY165164A (en) | 2018-02-28 |
| MX2014002204A (es) | 2014-06-11 |
| CO6920256A2 (es) | 2014-04-10 |
| BR112014004445B1 (pt) | 2022-11-22 |
| AR087953A1 (es) | 2014-04-30 |
| KR101949553B1 (ko) | 2019-02-18 |
| CN103874708B (zh) | 2018-07-10 |
| AU2012300220A1 (en) | 2013-05-02 |
| CA2846599A1 (en) | 2013-03-07 |
| CN103874708A (zh) | 2014-06-18 |
| WO2013033042A1 (en) | 2013-03-07 |
| SG11201400233TA (en) | 2014-08-28 |
| EP2748193A1 (en) | 2014-07-02 |
| US9403899B2 (en) | 2016-08-02 |
| JP6165143B2 (ja) | 2017-07-19 |
| IL231083A0 (en) | 2014-03-31 |
| HK1199267A1 (en) | 2015-06-26 |
| AU2012300220B2 (en) | 2015-09-10 |
| CL2014000480A1 (es) | 2014-10-03 |
| TW201326192A (zh) | 2013-07-01 |
| BR112014004445A2 (pt) | 2017-03-28 |
| US20130058961A1 (en) | 2013-03-07 |
| AU2012300220C1 (en) | 2016-11-10 |
| ES2624485T3 (es) | 2017-07-14 |
| IL231083B (en) | 2019-06-30 |
| EP2748193B1 (en) | 2017-02-01 |
| EA030251B1 (ru) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014002204A (es) | Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma. | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| IN2013MU02145A (es) | ||
| MX2018013128A (es) | Molecula de union al antigeno para promover la perdia de antigeno a traves de fc gamma riib. | |
| MX2019008065A (es) | Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida. | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| MX362039B (es) | Anticuerpos anti-il-23. | |
| NZ605400A (en) | Chimeric clotting factors | |
| MX2013010019A (es) | Metodo para aislamiento de osteopontina utilizando alimentos concentrados. | |
| MX342920B (es) | Metodo para purificar polipeptidos o inmunoconjugados activos. | |
| GB201407561D0 (en) | Transaction processing system,method and program | |
| MX2013007048A (es) | Metodo para el tratamiento de textiles con endoglucanasa. | |
| MX2014000531A (es) | Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13. | |
| PH12016500158A1 (en) | Methods for controlling fucosylation levels in proteins | |
| SG10201907901XA (en) | Antibodies, uses & methods | |
| SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
| MX2015006337A (es) | Metodos y composiciones para tratar enfermedades neurodegenerativas. | |
| MX368474B (es) | Uso de benralizumab para mejorar síntomas de asma. | |
| WO2013187971A3 (en) | Macrocycles | |
| MX2016002274A (es) | Procedimiento de purificacion para la hormona paratiroidea recombinante. | |
| MX351465B (es) | Un método para remover nitrógeno de amonio de agua con residuos orgánicos. | |
| WO2013009686A3 (en) | Methods for purification of arylsulfatase a | |
| MX2013008103A (es) | Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular. | |
| UA74021U (ru) | Способ лечения хронического вирусного гепатита с | |
| SE1630303A1 (en) | A new method for predicting uric acid composition in urinarystones using routine single energy computer tomography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BAXALTA INCORPORATED |
|
| FG | Grant or registration |